Effects of weight stigma on BMI and inflammatory markers among people living with obesity.

Objective: Weight stigma (WS) and prejudice are one of the most prevalent ways of discrimination among adults, comparable with rates of racial discrimination. Exposure to WS among patients with obesity (PWO) may make the adoption of healthy dietary patterns and regular physical activity even more challenging and, therefore, the achievement of weight loss. Additionally, WS could also induce physiological responses such as increased levels of inflammatory markers, due to stress exposure.

Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity.

Objective: Emotional eating (EE) and other abnormal eating patterns are highly prevalent among people living with obesity (PWO). In this sense, semaglutide, by acting on areas of the brain involved in the reward system and emotion regulation, could have the potential to ameliorate these eating patterns.

Method: 69 PWO attending an obesity clinic were evaluated baseline and after 3 months since the beginning of semaglutide.

GLP1 analogues among patients with overweight or obesity during lockdown.

Background And Objectives: One of the potential negative effects of a lockdown are changes in dietary and lifestyle patterns, which can lead to weight gain. Our objective was to assess the changes on dietary habits and eating patterns in a lockdown situation and their impact on weight. We aimed to determine whether the treatment with GLP1 analogues (aGLP1) could impact on these parameters.